CN114980864A - 用于药物递送的离子液体 - Google Patents

用于药物递送的离子液体 Download PDF

Info

Publication number
CN114980864A
CN114980864A CN202080094214.3A CN202080094214A CN114980864A CN 114980864 A CN114980864 A CN 114980864A CN 202080094214 A CN202080094214 A CN 202080094214A CN 114980864 A CN114980864 A CN 114980864A
Authority
CN
China
Prior art keywords
acid
composition
choline
ionic liquid
anion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080094214.3A
Other languages
English (en)
Chinese (zh)
Inventor
萨米尔·米特拉戈特里
帕维莫·安格桑提克
阿巴希尔普·曼达尔
伊登·E.L.·坦纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of CN114980864A publication Critical patent/CN114980864A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
CN202080094214.3A 2019-11-22 2020-11-19 用于药物递送的离子液体 Pending CN114980864A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962939088P 2019-11-22 2019-11-22
US62/939,088 2019-11-22
PCT/US2020/061185 WO2021102084A1 (en) 2019-11-22 2020-11-19 Ionic liquids for drug delivery

Publications (1)

Publication Number Publication Date
CN114980864A true CN114980864A (zh) 2022-08-30

Family

ID=73835783

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080094214.3A Pending CN114980864A (zh) 2019-11-22 2020-11-19 用于药物递送的离子液体

Country Status (9)

Country Link
US (1) US20240016735A1 (https=)
EP (1) EP4061338A1 (https=)
JP (2) JP2023503899A (https=)
KR (1) KR20220104766A (https=)
CN (1) CN114980864A (https=)
AU (1) AU2020388387A1 (https=)
CA (1) CA3158963A1 (https=)
IL (1) IL293145A (https=)
WO (1) WO2021102084A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4329732A1 (en) * 2021-04-28 2024-03-06 Haleon US IP LLC Ionic liquid salts of active pharmaceutical ingredients
WO2022256291A1 (en) * 2021-06-01 2022-12-08 President And Fellows Of Harvard College Hydrogel devices for drug delivery to the ear
CN113637708B (zh) * 2021-08-09 2023-07-25 中国科学院过程工程研究所 一种CRISPR-cas9基因编辑系统递送载体及其制备方法和应用
CN118382429A (zh) 2021-10-08 2024-07-23 哈佛大学校长及研究员协会 用于药物递送的离子液体
EP4429704A4 (en) 2021-11-10 2025-11-05 I2O Therapeutics Inc IONIC LIQUID COMPOSITIONS
CN114042032B (zh) * 2021-11-11 2024-04-26 武汉瑞佶生物科技有限公司 一种实现核酸皮肤递送的药物制剂及其制备方法和应用
CN114642733B (zh) * 2022-03-02 2023-08-22 中山大学 一种治疗雄激素源性脱发的组合物及其制备方法
CN118059118B (zh) * 2024-01-13 2025-07-22 张川 一种抑制nfkbiz基因表达的药物组合物和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019099837A1 (en) * 2017-11-17 2019-05-23 President And Fellows Of Harvard College Ionic liquids for internal delivery
WO2019183142A1 (en) * 2018-03-19 2019-09-26 Cage Bio Inc. Ionic liquid compositions for treatment of rosacea
WO2020205409A1 (en) * 2019-04-03 2020-10-08 President And Fellows Of Harvard College Ionic liquids for drug delivery

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
US7943129B2 (en) 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
CA2658673A1 (en) 2005-07-27 2008-02-01 Gerald J. Prud'homme Composition and method for prevention and treatment of type i and type ii diabetes
JP2008162899A (ja) * 2006-12-27 2008-07-17 Tokyo Univ Of Agriculture & Technology 生体関連化合物からなるイオン液体
EP2512518A1 (en) 2009-12-16 2012-10-24 Novo Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
JP6559394B2 (ja) * 2012-12-05 2019-08-14 ミヨシ油脂株式会社 親水性室温イオン液体とその用途
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
DK2931897T3 (en) 2012-12-12 2018-02-05 Broad Inst Inc CONSTRUCTION, MODIFICATION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTICAL APPLICATIONS
DK2931898T3 (en) 2012-12-12 2016-06-20 Massachusetts Inst Technology CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
AU2013359262C1 (en) 2012-12-12 2021-05-13 Massachusetts Institute Of Technology CRISPR-Cas component systems, methods and compositions for sequence manipulation
CA2894684A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of improved crispr-cas systems, methods and enzyme compositions for sequence manipulation in eukaryotes
CN105683376A (zh) 2013-05-15 2016-06-15 桑格摩生物科学股份有限公司 用于治疗遗传病状的方法和组合物
KR20250012194A (ko) 2013-06-17 2025-01-23 더 브로드 인스티튜트, 인코퍼레이티드 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
KR20160019553A (ko) 2013-06-17 2016-02-19 더 브로드 인스티튜트, 인코퍼레이티드 유사분열 후 세포의 질병 및 장애를 표적화하고 모델링하기 위한 시스템, 방법 및 조성물의 전달, 유전자 조작 및 최적화
US10449254B2 (en) * 2013-11-03 2019-10-22 The Regents Of The University Of California Ionic liquids for transdermal drug delivery
MX2016007325A (es) 2013-12-12 2017-07-19 Broad Inst Inc Composiciones y metodos de uso de sistemas crispr-cas en desordenes debidos a repeticion de nucleotidos.
JP6793547B2 (ja) 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物
WO2015168125A1 (en) 2014-04-28 2015-11-05 Recombinetics, Inc. Multiplex gene editing in swine
WO2015191693A2 (en) 2014-06-10 2015-12-17 Massachusetts Institute Of Technology Method for gene editing
EP3686279B1 (en) 2014-08-17 2023-01-04 The Broad Institute, Inc. Genome editing using cas9 nickases
WO2016049258A2 (en) 2014-09-25 2016-03-31 The Broad Institute Inc. Functional screening with optimized functional crispr-cas systems
WO2016094872A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Dead guides for crispr transcription factors
EP3889260A1 (en) 2014-12-12 2021-10-06 The Broad Institute, Inc. Protected guide rnas (pgrnas)
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
WO2016112242A1 (en) 2015-01-08 2016-07-14 President And Fellows Of Harvard College Split cas9 proteins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019099837A1 (en) * 2017-11-17 2019-05-23 President And Fellows Of Harvard College Ionic liquids for internal delivery
WO2019183142A1 (en) * 2018-03-19 2019-09-26 Cage Bio Inc. Ionic liquid compositions for treatment of rosacea
WO2020205409A1 (en) * 2019-04-03 2020-10-08 President And Fellows Of Harvard College Ionic liquids for drug delivery
CN113939273A (zh) * 2019-04-03 2022-01-14 哈佛大学校长及研究员协会 用于药物递送的离子液体

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ABHIRUP MANDAL等: "Treatment of psoriasis with NFKBIZ siRNA using topical ionic liquid formulations", 《SCIENCE ADVANCES》, vol. 6, no. 30, pages 1 - 9 *
AMRITA BANERJEE等: "Ionic liquids for oral insulin delivery", 《PNAS》, vol. 115, no. 28, pages 7296 - 7301, XP055696583, DOI: 10.1073/pnas.1722338115 *
EDEN E. L. TANNER等: "Design Principles of Ionic Liquids for Transdermal Drug Delivery", 《ADV. MATER.》, vol. 31, pages 1 - 10 *
MUKESH SHARMA等: "High concentration DNA solubility in bio-ionic liquids with long-lasting chemical and structural stability at room temperature", 《RSC ADV.》, vol. 5, 28 April 2015 (2015-04-28), pages 40546 - 40551 *
MUKESH SHARMA等: "High concentration DNA solubility in bio-ionic liquids with long-lasting chemical and structural stability at room temperature", 《RSC ADV.》, vol. 5, pages 40546 - 40551 *

Also Published As

Publication number Publication date
KR20220104766A (ko) 2022-07-26
JP2023503899A (ja) 2023-02-01
EP4061338A1 (en) 2022-09-28
WO2021102084A1 (en) 2021-05-27
JP2026021383A (ja) 2026-02-10
IL293145A (en) 2022-07-01
US20240016735A1 (en) 2024-01-18
CA3158963A1 (en) 2021-05-27
AU2020388387A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
CN114980864A (zh) 用于药物递送的离子液体
US20230093875A1 (en) Ionic liquids for internal delivery
CN113939273A (zh) 用于药物递送的离子液体
US8007790B2 (en) Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
WO2022143628A1 (zh) 预防或治疗抗肿瘤剂相关疾病或病症的方法
JP2024502948A (ja) ナノ材料のためのイオン化可能な脂質
US12533315B2 (en) Compositions comprising at least one ionic liquid, a polypeptide, and at least one non-ionic surfactant for protein delivery
TW202241438A (zh) 預防或治療ｅｇｆｒ功能異常相關的副作用的方法
JP2020536871A (ja) 尿素サイクル異常症、特にｏｔｃ欠損症を治療するための方法及び組成物
CN118382429A (zh) 用于药物递送的离子液体
HK40076473A (en) Ionic liquids for drug delivery
HK40113457A (zh) 用於药物递送的离子液体
WO2026030034A1 (en) Compositions and methods relating to amino acid ionic liquids
WO2025235741A1 (en) Compositions and methods for modulating mecp2 activity
TW202509035A (zh) Ｊａｋ抑制劑化合物及晶型

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40076473

Country of ref document: HK